Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered-Dose Inhaler in the Treatment of COVID-19 Patients

Ehtezazi, T (2021) The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered-Dose Inhaler in the Treatment of COVID-19 Patients. Recent Advances in Drug Delivery and Formulation, 15. pp. 1-13. ISSN 2667-3878

[img] Text
The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered Dose Inhaler in the Treatment of COVID19 Patients.pdf - Accepted Version
Restricted to Repository staff only until 30 November 2022.

Download (365kB)

Abstract

INTRODUCTION: Serious COVID-19 respiratory problems start when the virus reaches the alveolar level, where type II cells get infected and die. Therefore, virus inhibition at the alveolar level would help prevent these respiratory complications. METHOD: A literature search was conducted to collect physicochemical properties of small molecule compounds that could be used for the COVID-19 treatment. Compounds with a low melting point were selected along with those soluble in ethanol, hydrogen-bond donors, and acceptors. RESULTS: There are severe acute respiratory syndrome coronavirus inhibitors with physicochemical properties suitable for the formulation as an ultrafine pressurised metered-dose inhaler (pMDI). Mycophenolic acid, Debio 025, and cyclosporine A are prime candidates among these compounds. Cyclosporine A (hereafter cyclosporine) is a potent SARS-CoV-2 inhibitor, and it has been used for the treatment of COVID-19 patients, demonstrating an improved survival rate. Also, inhalation therapy of nebulised cyclosporine was tolerated, which was used for patients with lung transplants. Finally, cyclosporine has been formulated as a solution ultrafine pMDI. Although vaccine therapy has been started in most countries, inhalation therapies with non-immunological activities could minimise the spread of the disease and be used in vaccine-hesitant individuals. CONCLUSION: Ultrafine pMDI formulation of cyclosporine or Debio 025 should be investigated for the inhalation therapy of COVID-19.

Item Type: Article
Additional Information: The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/10.2174/2772574X12666211122113318
Uncontrolled Keywords: COVID-19; approved drugs; cyclosporine A; inhalation; pressurised metered-dose inhaler; regulatory tests
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Bentham Science Publishers
Related URLs:
Date Deposited: 11 Feb 2022 09:52
Last Modified: 11 Feb 2022 09:52
DOI or Identification number: 10.2174/2772574X12666211122113318
URI: https://researchonline.ljmu.ac.uk/id/eprint/16272

Actions (login required)

View Item View Item